Design Therapeutics (DSGN) Stock Price

Design Therapeutics Price

NASDAQ·CLOSED
14.33USD+0.34 (+2.40 %)
Market closed

For Design Therapeutics, the net margin of -3,600.0% is down versus -247.0% a few years ago. The consensus 12-month price target for Design Therapeutics is 13.26 USD, about 7.5% below where the stock trades today. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 199% above its 52-week low.

Design Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Design Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Design Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Design Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Design Therapeutics Stock Price History
DateDesign Therapeutics Price
8/10/202614.33 USD
8/7/202613.99 USD
8/6/202613.77 USD
8/5/202613.43 USD
8/4/202612.96 USD
8/3/202612.76 USD
7/31/202612.18 USD
7/30/202612.62 USD
7/29/202611.94 USD
7/27/202612.00 USD
7/23/202611.63 USD
7/22/202611.78 USD
7/21/202612.06 USD
7/20/202611.87 USD
7/17/202612.57 USD
7/16/202612.61 USD
7/15/202613.52 USD
7/14/202613.67 USD
7/13/202614.09 USD
7/10/202615.19 USD
7/9/202615.42 USD
7/8/202615.00 USD
7/7/202614.71 USD
7/6/202615.66 USD
7/2/202615.64 USD
7/1/202614.66 USD
6/30/202614.47 USD
6/29/202613.81 USD
6/26/202613.35 USD
6/25/202613.44 USD
6/24/202613.78 USD
6/23/202613.74 USD
6/22/202613.26 USD
6/18/202612.12 USD
6/17/202611.78 USD
6/16/202610.61 USD
6/15/202611.23 USD
6/12/202610.86 USD
6/11/202610.41 USD
6/10/202610.93 USD
6/9/202610.55 USD
6/8/202610.46 USD
6/5/202610.77 USD
6/4/202610.67 USD
6/3/202610.30 USD
6/2/202610.04 USD
6/1/202610.71 USD
5/29/202610.48 USD
5/28/202610.77 USD
5/27/202611.30 USD
5/26/202611.14 USD
5/22/202611.18 USD
5/21/202611.07 USD
5/20/202611.07 USD
5/19/202610.49 USD
5/18/202610.70 USD
5/15/202614.37 USD
5/14/202614.54 USD
5/13/202615.62 USD
5/12/202615.79 USD
5/11/202615.61 USD
5/8/202614.22 USD
5/7/202614.10 USD
5/6/202614.55 USD
5/5/202613.41 USD
5/4/202613.17 USD
5/1/202613.30 USD
4/30/202613.60 USD
4/29/202615.79 USD
4/28/202612.81 USD
4/27/202612.81 USD
4/24/202612.53 USD
4/23/202613.14 USD
4/22/202613.37 USD
4/21/202613.29 USD
4/20/202613.16 USD
4/17/202613.12 USD
4/16/202612.51 USD
4/15/202612.75 USD
4/14/202612.64 USD
4/13/202612.35 USD
4/10/202612.16 USD
4/9/202612.49 USD
4/8/202612.67 USD
4/7/202612.22 USD
4/6/202612.53 USD
4/2/202611.23 USD
4/1/202611.01 USD
3/31/202610.64 USD
3/30/202610.37 USD
3/27/202610.53 USD
3/26/202610.71 USD
3/25/202610.73 USD
3/24/202610.31 USD
3/23/202610.17 USD
3/20/202610.31 USD
3/19/202610.26 USD
3/18/202610.30 USD
3/17/202611.04 USD
3/16/202610.99 USD
3/13/202610.12 USD
3/12/202610.02 USD
3/11/202610.01 USD
3/10/20269.99 USD
3/9/202610.37 USD
3/6/202610.05 USD
3/5/202610.09 USD
3/4/202610.37 USD
3/3/202610.00 USD
3/2/202610.23 USD
2/27/202610.44 USD
2/26/202610.68 USD
2/25/202610.97 USD
2/24/202610.60 USD
2/23/202610.35 USD
2/20/202610.11 USD
2/19/202610.28 USD
2/18/202610.03 USD
2/17/202610.12 USD
2/13/202610.07 USD
2/12/202610.05 USD
2/11/202610.36 USD
2/10/202610.23 USD
2/9/202610.38 USD
2/6/202610.27 USD
2/5/20269.95 USD
2/4/202610.00 USD
2/3/202610.37 USD
2/2/202610.41 USD
1/30/202610.21 USD
1/29/202610.57 USD
1/28/202610.13 USD
1/27/202610.59 USD
1/26/202610.46 USD
1/23/202610.18 USD
1/22/202610.62 USD
1/21/20269.55 USD
1/20/20269.45 USD
1/16/20269.28 USD
1/15/20269.36 USD
1/14/20269.80 USD
1/13/20269.57 USD
1/12/20269.12 USD
1/9/20269.39 USD
1/8/20269.18 USD
1/7/20269.87 USD
1/6/20268.82 USD
1/5/20268.69 USD
1/2/20269.10 USD
12/31/20259.38 USD
12/30/20259.79 USD
12/29/20259.79 USD
12/26/20259.63 USD
12/24/20259.74 USD
12/23/20259.60 USD
12/22/20259.96 USD
12/19/20259.68 USD
12/18/20259.01 USD
12/17/20258.86 USD
12/16/20259.62 USD
12/15/20259.12 USD
12/12/20259.43 USD
12/11/20259.24 USD
12/10/20259.42 USD
12/9/20259.27 USD
12/8/20259.86 USD
12/5/20259.77 USD
12/4/20259.82 USD
12/3/20259.77 USD
12/2/20258.94 USD
12/1/20258.95 USD
11/28/20259.39 USD
11/26/20259.37 USD
11/25/20259.41 USD
11/24/20258.64 USD
11/21/20258.35 USD
11/20/20257.87 USD
11/19/20257.34 USD
11/18/20257.59 USD
11/17/20257.43 USD
11/14/20257.37 USD
11/13/20257.06 USD
11/12/20257.61 USD
11/11/20257.76 USD
11/10/20257.43 USD
11/7/20257.56 USD
11/6/20256.87 USD
11/5/20256.55 USD
11/4/20256.24 USD
11/3/20256.55 USD
10/31/20256.70 USD
10/30/20256.53 USD
10/29/20256.49 USD
10/28/20256.68 USD
10/27/20256.97 USD
10/24/20255.73 USD
10/23/20255.70 USD
10/22/20255.53 USD
10/21/20255.63 USD
10/20/20255.83 USD
10/17/20255.74 USD
10/16/20256.17 USD
10/15/20256.71 USD
10/14/20256.62 USD
10/13/20256.49 USD
10/10/20256.75 USD
10/9/20257.12 USD
10/8/20256.94 USD
10/7/20256.49 USD
10/6/20256.35 USD
10/3/20256.11 USD
10/2/20256.02 USD
10/1/20256.79 USD
9/30/20257.53 USD
9/29/20256.85 USD
9/26/20256.57 USD
9/25/20256.11 USD
9/24/20256.44 USD
9/23/20256.02 USD
9/22/20256.35 USD
9/19/20256.05 USD
9/18/20256.25 USD
9/17/20255.95 USD
9/16/20255.85 USD
9/15/20255.86 USD
9/12/20256.03 USD
9/11/20255.96 USD
9/10/20256.13 USD
9/9/20256.64 USD
9/8/20255.82 USD
9/5/20256.45 USD
9/4/20256.11 USD
9/3/20255.96 USD
9/2/20255.73 USD
8/29/20255.53 USD
8/28/20255.64 USD
8/27/20255.29 USD
8/26/20255.41 USD
8/25/20255.20 USD
8/22/20255.26 USD
8/21/20255.15 USD
8/20/20254.79 USD
8/19/20255.17 USD
8/18/20255.40 USD
8/15/20255.33 USD
8/14/20255.16 USD
Access this data via the Eulerpool API
Get Free API Key

Design Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
0.00 USD
-67.59 M USD
-63.31 M USD
Jan 1, 2023
0.00 USD
-78.19 M USD
-66.86 M USD
Jan 1, 2024
0.00 USD
-62.00 M USD
-50.00 M USD
Jan 1, 2025 (e)
48.53 M USD
-84.97 M USD
-74.21 M USD
Jan 1, 2026 (e)
117.33 M USD
-96.39 M USD
-77.52 M USD
Jan 1, 2027 (e)
204.78 M USD
-128.56 M USD
-93.24 M USD
Jan 1, 2028 (e)
8.40 M USD
-181.06 M USD
-111.25 M USD
Jan 1, 2029 (e)
72.09 M USD
-185.38 M USD
-85.78 M USD

Design Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 14, 2026, 12:01 AM
 
REVENUEM USD
REVENUE GROWTH%
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2019202020212022202320242025e2026e2027e2028e2029e2030e2031e
––––––48.00117.00204.008.0072.00235.00500.00
–––––––143.7574.36-96.08800.00226.39112.77
-1.00-8.00-35.00-67.00-78.00-62.00-84.00-96.00-128.00-181.00-185.00-70.00–
––––––-175.00-82.05-62.75-2,262.50-256.94-29.79–
-2.00-8.00-35.00-63.00-66.00-50.00-74.00-77.00-93.00-111.00-85.00-2.0063.00
–300.00337.5080.004.76-24.2448.004.0520.7819.35-23.42-97.65-3,250.00
53.8253.8245.9455.7155.9857.0057.0057.0057.0057.0057.0057.0057.00
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Design Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Design Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Design Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Design Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Design Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Design Therapeutics stock margins

The Design Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Design Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Design Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
0.00 %
-3,621.74 %
-3,600.00 %
Jan 1, 2021
0.00 %
- %
- %
Jan 1, 2022
0.00 %
- %
- %
Jan 1, 2023
0.00 %
- %
- %
Jan 1, 2024
0.00 %
- %
- %
Jan 1, 2025 (e)
0.00 %
-175.10 %
-152.93 %
Jan 1, 2026 (e)
0.00 %
-82.15 %
-66.07 %
Jan 1, 2027 (e)
0.00 %
-62.78 %
-45.53 %

Design Therapeutics Stock Revenue, EBIT, Earnings per Share

The Design Therapeutics earnings per share therefore indicates how much revenue Design Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.00 USD
-0.15 USD
-0.15 USD
Jan 1, 2021
0.00 USD
-0.78 USD
-0.77 USD
Jan 1, 2022
0.00 USD
-1.21 USD
-1.14 USD
Jan 1, 2023
0.00 USD
-1.40 USD
-1.19 USD
Jan 1, 2024
0.00 USD
-1.09 USD
-0.88 USD
Jan 1, 2025 (e)
0.85 USD
-1.49 USD
-1.30 USD
Jan 1, 2026 (e)
2.06 USD
-1.69 USD
-1.36 USD
Jan 1, 2027 (e)
3.59 USD
-2.26 USD
-1.64 USD

Design Therapeutics business model & stock analysis

Design Therapeutics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Design Therapeutics Employees
Details
Date
Design Therapeutics Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Design Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Design Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Design Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Design Therapeutics shares outstanding

The number of shares of Design Therapeutics was 57 M in 2025. This indicates how many shares Design Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
53.82 M Stocks
Jan 1, 2021
45.94 M Stocks
Jan 1, 2022
55.71 M Stocks
Jan 1, 2023
55.98 M Stocks
Jan 1, 2024
57.00 M Stocks
Jan 1, 2025 (e)
57.00 M Stocks
Jan 1, 2026 (e)
57.00 M Stocks
Jan 1, 2027 (e)
57.00 M Stocks

Current Design Therapeutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
81.82 % (9)
Hold
18.18 % (2)
Sell
0.00 % (0)
12M Price Target
13.26
Last Price
14.56
Currency
USD
12M Return Potential
-8.93 %
LTM Return
0 %

Design Therapeutics Analyst Rating Actions

DateFirmActionRatingReliability
5/4/2026
Oppenheimer
Oppenheimer
MaintainedOutperform65
3/10/2026
RBC Capital
RBC Capital
MaintainedOutperform52
12/3/2025
Leerink Partners
Leerink Partners
UpgradeMarket PerformOutperform–
11/20/2025
RBC Capital
RBC Capital
UpgradeSector PerformOutperform52
11/6/2025
RBC Capital
RBC Capital
MaintainedSector Perform52
8/6/2024
RBC Capital
RBC Capital
MaintainedSector Perform52
5/7/2024
Piper Sandler
Piper Sandler
UpgradeNeutralOverweight51
3/20/2024
Wedbush
Wedbush
MaintainedNeutral59
3/20/2024
RBC Capital
RBC Capital
MaintainedSector Perform52
11/14/2023
RBC Capital
RBC Capital
MaintainedSector Perform52

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Design Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/10/2026-0.35USD-0.00USD-2026 Q2
5/11/2026-0.33USD-0.00USD-2026 Q1
3/17/2026-0.36USD-0.00USD-2025 Q4
11/11/2024-0.25USD-0.00USD-2024 Q3
5/7/2024-0.34USD-0.00USD-2024 Q1
3/12/2024-0.32USD-0.00USD-2023 Q4
8/7/2023-0.36USD-0.00USD-2023 Q2

EESG©

Eulerpool ESG Scorecard© for the Design Therapeutics stock

41/100
40
Environment
71
Social
12
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Design Therapeutics shareholder structure

% Name
11.44996%
SR One Capital Management, LP
SR One Capital Management, LP
9.42457%
Point72 Asset Management, L.P.
Point72 Asset Management, L.P.
4.38596%
Logos Global Management LP
Logos Global Management LP
3.91772%
Baker Bros. Advisors LP
Baker Bros. Advisors LP
3.26024%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
2.86125%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
...

Design Therapeutics Beneficial Ownership Filings (SEC 13D/G)

Free Float
52.6%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
13.80%
of 5 Pages
of 5 Pages
SEC ↗
10.70%
Simeon George
Simeon George
SEC ↗
10.60%
SR One Capital Partners I, LP
SR One Capital Partners I, LP
SEC ↗
10.60%
SR One Capital Management, LLC
SR One Capital Management, LLC
SEC ↗
10.60%
SR One Capital Fund I Aggregator, LP
SR One Capital Fund I Aggregator, LP
SEC ↗
9.20%
Cormorant Asset Management, LP
Cormorant Asset Management, LP
SEC ↗
9.20%
Bihua Chen
Bihua Chen
SEC ↗
6.90%
Star Irrevocable Trust #1 dated April 22, 2019
Star Irrevocable Trust #1 dated April 22, 2019
SEC ↗
6.90%
Light Irrevocable Trust #1 dated April 22, 2019
Light Irrevocable Trust #1 dated April 22, 2019
SEC ↗
6.90%
Jason Howerton
Jason Howerton
SEC ↗

Design Therapeutics Executives and Management Board

8 members · avg. age 55 · 13 % women

SJ

Dr. Sean Jeffries (45)

Chief Operating Officer

1.32 M USD

Management

PS

Dr. Pratik Shah (55)

Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer · since 2017

789,800.00 USD
CS

Dr. Christopher Storgard (59)

Chief Medical Officer

–

Board of Directors

SG

Dr. Simeon George (48)

Lead Independent Director

137,980.00 USD
JS

Mr. John Schmid (62)

Independent Director

117,980.00 USD
RL

Dr. Rodney Lappe (70)

Independent Director

116,980.00 USD
HB

Dr. Heather Berger (50)

Independent Director

105,105.00 USD
JG

Mr. Justin Gover (54)

Director

–

Frequently asked questions about Design Therapeutics

Analysts currently set an average price target of 13.26 USD for the Design Therapeutics stock (median: 13.26 USD), implying -8.9 % versus the latest price. The consensus is based on 11 analyst ratings.

Design Therapeutics Analyst Price Targets 2026

11 analysts currently rate the Design Therapeutics stock: 9 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Design Therapeutics to generate revenue of 117.33 M USD and earnings per share of -1.36 USD.

Design Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the Design Therapeutics share trades at 12.42 EUR (14.33 USD).

The Design Therapeutics share (DSGN) is listed on 1 stock exchanges, including: NASDAQ (DSGN).

No history available for Design Therapeutics.

The expected revenue of Design Therapeutics is 117.33 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Design Therapeutics is -77.52 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Design Therapeutics is currently -10.54. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Design Therapeutics stock.

The price-to-sales ratio (P/S) of Design Therapeutics is currently 6.96. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Design Therapeutics stock.

The Eulerpool Quality Score for Design Therapeutics is 2/10.

The ISIN of Design Therapeutics is US25056L1035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Design Therapeutics is DSGN. The ticker symbol is used to trade Design Therapeutics shares on the stock exchange.

Design Therapeutics paid dividends every year for the past 0 years.

Design Therapeutics is assigned to the 'Health' sector.

The dividends of Design Therapeutics are distributed in USD.

All fundamentals and in-depth analysis of Design Therapeutics

Our stock analysis for Design Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Design Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Design Therapeutics Stock
Design Therapeutics Revenue→
Design Therapeutics Stock
Design Therapeutics Net Income→
Design Therapeutics Stock
Design Therapeutics P/E→
Design Therapeutics Stock
Design Therapeutics P/S→
Design Therapeutics Stock
Design Therapeutics EBIT→
Design Therapeutics Stock
Design Therapeutics Dividend→
Design Therapeutics Stock
Design Therapeutics Directors Dealings→
Design Therapeutics Stock
Design Therapeutics Stocks→
Design Therapeutics Stock
Design Therapeutics Market capitalization→
Design Therapeutics Stock
Design Therapeutics Debt→
Design Therapeutics Stock
Design Therapeutics Liabilities→
Design Therapeutics Stock
Design Therapeutics Equity→
Design Therapeutics Stock
Design Therapeutics AAQS→
Design Therapeutics Stock
Design Therapeutics Employees→
Design Therapeutics Stock
Design Therapeutics ROE→
Design Therapeutics Stock
Design Therapeutics ROA→
Design Therapeutics Stock
Design Therapeutics ROCE→
Design Therapeutics Stock
Design Therapeutics News→
Design Therapeutics Stock
Design Therapeutics Analyst Price Targets→

Health Stocks

Devonian Health GroupDermata TherapeuticsDevyser DiagnosticsDermapharm HoldingDexcomDENTSPLY SIRONADextech MedicalDentium CoDezhan Healthcare CoDentis CoDhanvantri Jeevan RekhaDental Patient Care AmericaAll Stocks A–Z →